Longboard Pharmaceuticals (LBPH) Stock

NEW YORK, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

LBPH stock soars 52% on announcing that it is set to be acquired by Lundbeck for a total consideration of $2.6 billion to bolster the latter's neuro pipeline.

NEW YORK , Oct. 14, 2024 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Longboard Pharmaceuticals, Inc. (NASDAQ: LBPH) and its board of directors concerning the proposed acquisition of the company by H. Lundbeck A/S.

MILWAUKEE--(BUSINESS WIRE)--Ademi LLP is investigating Longboard (NASDAQ: LBPH) for possible breaches of fiduciary duty and other violations of law in its transaction with Lundbeck. Click here to learn how to join our investigation or call Guri Ademi toll-free at 866-264-3995. There is no cost or obligation to you. In the transaction, Longboard shareholders will receive only $60.00 per share in a tender offer that values the Longboard at approximately $2.6 billion equity value. The transaction.

VALBY, Denmark & LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #Epilepsy--H. Lundbeck A/S (Lundbeck) and Longboard Pharmaceuticals, Inc (NASDAQ: LBPH) (Longboard) today announced an agreement for Lundbeck to acquire Longboard. Under the terms of the agreement, Lundbeck will commence a tender offer for all outstanding shares of Longboard common stock, whereby Longboard shareholders will be offered a payment of USD 60.00 per share in cash. The transaction is valued at approximately USD 2.6 billion equity value and USD.

Q2 2024 Longboard Pharmaceuticals Inc Earnings Call and Discussi {"@context":"http://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"GuruFocus.com","item":"https://www.gurufocus.com"},{"@type":"ListItem","position":2,"name":"Latest News","item":"https://www.gurufocus.com/latest-news"},{"@type":"ListItem","position":3,"name":"U.S.","item":"https://www.gurufocus.com/latest-news/usa"},{"@type":"ListItem","position":4,"name":"Biotechnology","item":"https://www.gurufocus.com/latest-news/usa/biotechnology"},{"@type":"ListItem","position":5,"name":"NAS:LBPH","item":"https://www.gurufocus.

The FDA grants orphan drug and rare pediatric disease designations to LBPH's lead pipeline drug for the treatment of Dravet Syndrome.

Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH ) Q2 2024 Earnings Call Transcript August 1, 2024 4:30 PM ET Company Participants Brandi Roberts - Executive Vice President and Chief Financial Officer Kevin Lind - President and Chief Executive Officer Randall Kaye - Executive Vice President and Chief Medical Officer Conference Call Participants Laura Chico - Wedbush Securities Joel Beatty - Baird Gavin Clark-Gartner - Evercore Kalpit Patel - B. Riley Securities David Hoang - Citigroup Yatin Suneja - Guggenheim Securities Operator Good afternoon, ladies and gentlemen, and welcome to the Longboard Pharmaceuticals Earnings and Corporate Update Call.

If you are looking for stocks that are well positioned to maintain their recent uptrend, Longboard Pharmaceuticals (LBPH) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.